Valentin Fuster – författare

A rapid increase in our understanding of the biology of platelets and their role in disease in recent years has been paralleled by increasing successes with established platelet-modifying therapies in many clinical conditions. This text focuses on the clinical role of platelets in a wide variety of haematologic, cardiovascular and other disorders, providing a practical, clinically relevant handbook for all clinicians and researchers interested in platelets and their role in disease. Covering platelet physiology, bleeding disorders, thrombotic disorders and antithrombotic therapy. Chapters cover all the conventional and less conventional aspects of platelet involvement in disease, with an emphasis on recent clinical developments. Clear take home messages have been included in each chapter to aid clinical practice. With contributions from leading experts across three continents, Platelets in Hematologic and Cardiovascular Disorders is an up-to-date, well illustrated, practical resource for everyone involved in clinical practice with platelet disorders.

Edited by Valentin Fuster, former Chairman of the American Heart Association's Committee on Vascular Lesions, Assessing and Modifying the Vulnerable Atherosclerotic Plaque explores the cutting-edge developments in a steadily advancing field.This monograph is a valuable multidisciplinary resource, written by experts in the fields of mechanical and electrical engineering, pathology, neurology, imaging, clinical and vascular biology, physics, radiology and surgery. The book's nineteen chapters and five transcribed Panel Discussions provides a wealth of information on the identification and treatment of atherosclerotic plaques, including the latest diagnostic applications of numerous imaging techniques, the reasons for selecting a particular method, and what can be learned from the imaging results. Important insights into the structural and cellular components of vulnerable plaque are presented, as well as an examination of factors/activities that trigger thrombosis.

The landmark text that belongs in the hands of every cardiologist―fully updated and reorganized to make it more patient-centric than ever

A Doody's Core Title for 2024 & 2023!

World-famous for its authority and clinical relevance, Fuster and Hurst’s The Heart is cardiology’s longest continuously published reference book. Written to meet the ever-changing needs of cardiologists, fellows, and interns, this trusted classic offers a solid foundation in cardiovascular medicine and complete coverage of all major cardiovascular topics.

This fifteenth edition presents a greater focus on the practicalities of patient care. Additionally, the content is ordered in a more methodical pattern, from mechanism to management. Reflecting the latest technical, therapeutic, and clinical advances, Fuster and Hurst’s The Heart provides invaluable concise summaries of major new trials and guidelines.

Authoritative Coverage and Unmatched Utility:

Central IllustrationsNew section on cardiovascular critical careNew chapter "Cardiovascular Disease and COVID-19"Chapter summariesACC/AHA/ESC guidelines in all chapters1,200+ photos and illustrations

Sections Include:

Risk Factors for Cardiovascular DiseaseAtherosclerosis and Coronary Heart DiseaseDiseases of the Great Vessels and Peripheral VesselsValvular Heart DiseaseRhythm and Conduction AbnormalitiesHeart FailureDiseases of the PericardiumCardiopulmonary DiseaseCritical Cardiovascular CareAdult Congenital Heart DiseaseSpecial Populations and Topics in Cardiovascular Disease

A Doody's Core Title for 2022!

Society-sanctioned guidelines on care are valuable tools, but accessing key information from the often complicated statements has been a daunting task. Now, practitioners and their institutions have a clear path to successful application of guidelines from the American Heart Association. This book outlines the key AHA guidelines, Statements, and Performance Measures and includes comparisons with the associated European guidelines. This book also has a strong online component, which will alert users who sign up to new updates to the guidelines and other relevant information. It will also have links through to the full guidelines and statements.

This issue of Medical Clinics of North America provides the latest essential updates on coronary risk factors. The following key questions are answered. Are new biomarkers informative? LDL: the lower the better? How important is HDL? How much credit does triglyceride deserve? How important is family history of coronary disease? How important is age in determining coronary risk factors? Endothelial progenitor cells, menopause, and coronary risk factors? What is the role of imaging in prevention of coronary artery disease? Is genomics ready for primetime? Pediatric statinization? Individualized statinization? Polypill for some, polypill for all?

This Annals volume stems from the two-day conference "Evolving Challenges in Promoting Cardiovascular Health" sponsored by The New York Academy of Sciences, "la Caixa" Foundation, and the International Center for Scientific Debate (ICSD), which took place November 4-5, 2011 in Barcelona, Spain.  Leading and emerging investigators working on the fields of cardiology, vascular disease, inflammation, metabolic disorders, hematology, imaging, regenerative medicine, stem cell research, epidemiology, and nutrition, among others, address novel issues, current challenges, and future directions in the prevention, treatment, and management of the evolving global epidemic of cardiovascular disease. The papers in this volume explore the promotion of cardiovascular health through molecular biology, clinical pathophysiology, and population research. NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749-6632&doi=10.1111/(ISSN)1749-6632.ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.

Cardiovascular disease (CVD), once thought to be confined primarily to industrialized nations, has emerged as a major health threat in developing countries. Cardiovascular disease now accounts for nearly 30 percent of deaths in low and middle income countries each year, and is accompanied by significant economic repercussions. Yet most governments, global health institutions, and development agencies have largely overlooked CVD as they have invested in health in developing countries. Recognizing the gap between the compelling evidence of the global CVD burden and the investment needed to prevent and control CVD, the National Heart, Lung, and Blood Institute (NHLBI) turned to the IOM for advice on how to catalyze change. In this report, the IOM recommends that the NHLBI, development agencies, nongovernmental organizations, and governments work toward two essential goals: * creating environments that promote heart healthy lifestyle choices and help reduce the risk of chronic diseases, and * building public health infrastructure and health systems with the capacity to implement programs that will effectively detect and reduce risk and manage CVD.To meet these goals, the IOM recommends several steps, including improving cooperation and collaboration; implementing effective and feasible strategies; and informing efforts through research and health surveillance. Without better efforts to promote cardiovascular health, global health as a whole will be undermined.